Nivolumab available to hundreds of patients with head and neck cancer
Nivolumab seems to be causing quite the stir in recent news.
Recently, NICE and NHS Wales have approved the drugs for use with patients with lung cancer.
Nivolumab works by targeting proteins and stimulating the body’s immune systems so it attacks cancerous cells.
Originally, evidence supporting the use of nivolumab to treat patients with head and neck cancer was uncertain. However, the National Institute for Health and Care Excellence (NICE) invited Bristol-Myers Squibb submit a CDF proposal that addressed the uncertainties in evidence.
Therefore, whilst the drug is with the CDF, head and neck cancer patients now have access to the it via the NHS. During the time the drug is with the CDF, further data will be collected on the suitability for head and neck cancer patients. A clinical trial will also take place that will address the uncertainties in using nivolumab to treat head and neck cancer.
Speaking on the drug, Professor Carole Longson, director of the Centre for Health Technology Evaluation at NICE said:
“Nivolumab is an innovative drug that continues to draw attention, but its clinical evidence for some types of cancer can be uncertain. I am pleased the company has worked with us and NHS England to develop a managed access agreement and that we have found a way to provide for patients despite these uncertainties.”
To keep uptodate with all the latest innovations in the oncology market, register for your free ticket to attend the European Oncology Convention 2018 at ExCeL, London on the 6th & 7th June 2018.
If you are a company that specialises in oncology treatments and technology and want the opportunity to meet thousands of senior decision makers in oncology actively looking to invest in the industry, contact Nick Woore, Event Director, now on:
Tel: 0117 929 6097